Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncopeptides AB ( (SE:ONCO) ) has shared an update.
Oncopeptides AB announced a change in the number of votes due to the conversion of class C shares to ordinary shares as part of its incentive program. This adjustment reflects the company’s ongoing efforts to align its share structure with its strategic goals, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. Utilizing its proprietary Peptide Drug Conjugate platform, the company develops compounds that deliver cytotoxic agents into cancer cells. Oncopeptides’ flagship drug is being commercialized in Europe, with partnership agreements in South Korea, the Middle East, Africa, and other regions. Founded in 2000, the company operates in several European countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 3,992,867
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.44B
For detailed information about ONCO stock, go to TipRanks’ Stock Analysis page.